Sage Therapeutics Dirección

Dirección controles de criterios 1/4

El CEO de Sage Therapeutics es Barry Greene , nombrado en Dec 2020, tiene una permanencia de 3.92 años. compensación anual total es $6.24M, compuesta por 12.8% salario y 87.2% primas, incluidas acciones y opciones de la empresa. posee directamente un 0.14% de las acciones de la empresa, por valor de €419.04K. La antigüedad media del equipo directivo y de la junta directiva es de 1.3 años y 9.3 años, respectivamente.

Información clave

Barry Greene

Chief Executive Officer (CEO)

US$6.2m

Compensación total

Porcentaje del salario del CEO	12.8%
Permanencia del CEO	3.9yrs
Participación del CEO	0.1%
Permanencia media de la dirección	1.3yrs
Promedio de permanencia en la Junta Directiva	9.3yrs

Actualizaciones recientes de la dirección

Recent updates

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de Barry Greene en comparación con los beneficios de Sage Therapeutics?
Fecha	Compensación total	Salario	Ingresos de la empresa
Sep 30 2024	n/a	n/a	-US$338m
Jun 30 2024	n/a	n/a	-US$446m
Mar 31 2024	n/a	n/a	-US$503m
Dec 31 2023	US$6m	US$799k	-US$541m
Sep 30 2023	n/a	n/a	-US$656m
Jun 30 2023	n/a	n/a	-US$592m
Mar 31 2023	n/a	n/a	-US$558m
Dec 31 2022	US$6m	US$761k	-US$533m
Sep 30 2022	n/a	n/a	-US$510m
Jun 30 2022	n/a	n/a	-US$503m
Mar 31 2022	n/a	n/a	-US$484m
Dec 31 2021	US$59m	US$735k	-US$458m
Sep 30 2021	n/a	n/a	US$642m
Jun 30 2021	n/a	n/a	US$666m
Mar 31 2021	n/a	n/a	US$637m
Dec 31 2020	US$836k	US$53k	US$606m

Compensación vs. Mercado: La compensación total de Barry($USD6.24M) está por encima de la media de empresas de tamaño similar en el mercado German ($USD1.03M).

Compensación vs. Ingresos: La compensación de Barry ha aumentado mientras la empresa no es rentable.

CEO

Barry Greene (61 yo)

3.9yrs

Permanencia

US$6,237,491

Compensación

Mr. Barry E. Greene serves as President and Chief Executive Officer at Sage Therapeutics, Inc. since December 15, 2020 and its Director since October 1, 2020. Mr. Greene joined the Sage Therapeutics, Inc....

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Barry Greene	President	3.9yrs	US$6.24m	0.14% € 419.0k
Christopher Benecchi	Chief Operating Officer	no data	US$2.28m	0.0081% € 24.6k
Laura Gault	Chief Medical Officer	2.1yrs	US$1.27m	0.018% € 52.9k
Mike Quirk	Chief Scientific Officer	1.3yrs	sin datos	sin datos
Ashley Kaplowitz	Director of Investor Relations	no data	sin datos	sin datos
Gregory Shiferman	Senior VP & General Counsel	no data	sin datos	sin datos
Pamela Herbster	VP & Head of People	less than a year	sin datos	sin datos
Helen Colquhoun	Senior Vice President of Drug Safety & Pharmacovigilance	no data	sin datos	sin datos
Vanessa Procter	Senior Vice President of Corporate Affairs	3yrs	sin datos	sin datos
Aaron Koenig	Medical Director of Early Clinical Development	no data	sin datos	sin datos
Maren Killackey	Senior Analyst of Investor Relation	no data	sin datos	sin datos
Jeff Boyle	Investor Contact	no data	sin datos	sin datos

1.3yrs

Permanencia media

55yo

Promedio de edad

Equipo directivo experimentado: El equipo directivo de SG7 no se considera experimentado ( 1.3 años antigüedad media), lo que sugiere un nuevo equipo.

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Barry Greene	President	4.1yrs	US$6.24m	0.14% € 419.0k
Michael Cola	Independent Director	10.2yrs	US$440.05k	0% € 0
James Frates	Independent Director	10.5yrs	US$435.05k	0.0046% € 14.0k
David Farb	Member of Scientific Advisory Board	no data	sin datos	sin datos
Geno Germano	Independent Chair of the Board	8.3yrs	US$417.55k	0% € 0
Michael Rogawski	Member of Scientific Advisory Board	no data	sin datos	sin datos
James Audia	Member of Scientific Advisory Board	no data	sin datos	sin datos
Christine Marx	Member of Scientific Advisory Board	no data	sin datos	sin datos
A. Morrow	Member of Scientific Advisory Board	no data	sin datos	sin datos
Stephen Moss	Member of Scientific Advisory Board	no data	sin datos	sin datos
Scott Runyon	Member of Scientific Advisory Board	no data	sin datos	sin datos
Donald Stein	Member of Scientific Advisory Board	no data	sin datos	sin datos

9.3yrs

Permanencia media

63yo

Promedio de edad

Junta con experiencia: La junta directiva de SG7 se considera experimentada (9.3 años de antigüedad promedio).

Sage Therapeutics Dirección

Dirección controles de criterios 1/4

Información clave

Actualizaciones recientes de la dirección

Sage Therapeutics, Inc.'s CFO Kimi Iguchi to Depart Amid Leadership Changes

Sage Therapeutics, Inc., Annual General Meeting, Jun 10, 2024

Sage Therapeutics, Inc. Announces Changes to Board of Directors

Insufficient new directors

President recently bought €492k worth of stock

Sage Therapeutics, Inc. Announces Resignation of Jeffrey M. Jonas as Chief Innovation Officer

Recent updates

Sage Therapeutics Announces Topline Results from the Phase 2 DIMENSION Study of Dalzanemdor (SAGE-718) in the Treatment of Cognitive Impairment Associated with Huntington’s Disease

Sage Therapeutics, Inc.'s CFO Kimi Iguchi to Depart Amid Leadership Changes

Sage Therapeutics, Inc. to Report Q3, 2024 Results on Oct 29, 2024

Sage Therapeutics Announces Topline Results from the Phase 2 Lightwave Study of Dalzanemdor (Sage-718) in the Treatment of Mild Cognitive Impairment and Mild Dementia in Alzheimer’S Disease

Sage Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $250 million.

Holzer & Holzer, LLC Announces a Class Action Lawsuit Has Been Filed Against Sage Therapeutics, Inc

New minor risk - Shareholder dilution

Second quarter 2024 earnings released: US$1.70 loss per share (vs US$2.68 loss in 2Q 2023)

Sage Therapeutics and Biogen Announce Topline Results from Phase 2 KINETIC 2 Study of Sage-324 (BIIB124) for the Treatment of Essential Tremor

Sage Therapeutics, Inc.(NasdaqGM:SAGE) dropped from Russell 2500 Growth Index

Sage Therapeutics, Inc. Announces Topline Results from the Phase 2 SURVEYOR Study

Sage Therapeutics, Inc., Annual General Meeting, Jun 10, 2024

First quarter 2024 earnings released: US$1.80 loss per share (vs US$2.46 loss in 1Q 2023)

Sage Therapeutics, Inc. Announces Topline Results from Phase 2 PRECEDENT Study of DalzanemDor (SAGE-718) in the Treatment of Mild Cognitive Impairment in Parkinson's Disease

Sage Therapeutics, Inc. to Report Q1, 2024 Results on Apr 25, 2024

Full year 2023 earnings released: US$9.05 loss per share (vs US$8.98 loss in FY 2022)

Sage Therapeutics, Inc. to Report Q4, 2023 Results on Feb 14, 2024

Sage Therapeutics, Inc. Announces Changes to Board of Directors

Sage Therapeutics, Inc. and Biogen Inc. Announces ZURZUVAE (Zuranolone) 50 mg (Two 25 mg Capsules Per Day) CIV

Insufficient new directors

Sage Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $250 million.

Sage Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $250 million.

Sage Therapeutics, Inc. to Report Q3, 2023 Results on Nov 07, 2023

Sage Therapeutics, Inc. Announces U.S. Food and Drug Administration Granted Sage-718 Orphan Drug Designation for the Treatment of Huntington's Disease

Sage Therapeutics, Inc. Announces Reduction of the Workforce by Approximately 40%

Second quarter 2023 earnings released: US$2.68 loss per share (vs US$2.13 loss in 2Q 2022)

Sage Therapeutics, Inc. to Report Q2, 2023 Results on Aug 07, 2023

New minor risk - Share price stability

First quarter 2023 earnings released: US$2.46 loss per share (vs US$2.07 loss in 1Q 2022)

Full year 2022 earnings released: US$8.98 loss per share (vs US$7.81 loss in FY 2021)

Biogen Inc. and Sage Therapeutics, Inc. Announce FDA Accepts Filing of New Drug Application and Grants Priority Review of Zuranolone in the Treatment of Major Depressive Disorder and Postpartum Depression

Sage Therapeutics, Inc. to Report Q4, 2022 Results on Feb 16, 2023

Sage Therapeutics and Biogen Complete Rolling Submission of New Drug Application for Zuranolone in the Treatment of Major Depressive Disorder and Postpartum Depression

President recently bought €492k worth of stock

Third quarter 2022 earnings released: US$2.31 loss per share (vs US$2.21 loss in 3Q 2021)

Sage Therapeutics, Inc. Announces Resignation of Jeffrey M. Jonas as Chief Innovation Officer

Sage Therapeutics Appoints Laura M. Gault as Chief Medical Officer

Sage Therapeutics, Inc. to Report Q3, 2022 Results on Nov 08, 2022

Sage Therapeutics and Biogen Present Further Analyses from Phase 3 Skylark Study of Zuranolone in Postpartum Depression At the European College of Neuropsychopharmacology (Ecnp) Congress

Second quarter 2022 earnings released: US$2.13 loss per share (vs US$1.83 loss in 2Q 2021)

Sage Therapeutics, Inc. Enters into Settlement Agreement

Sage Therapeutics, Inc.(NasdaqGM:SAGE) dropped from Russell 1000 Dynamic Index

Sage Therapeutics, Inc. Provides Zuranolone New Drug Application Update

Sage Therapeutics and Biogen Announce that the Phase 3 SKYLARK Study of Zuranolone in Postpartum Depression Met its Primary and All Key Secondary Endpoints

Insider recently bought €239k worth of stock

First quarter 2022 earnings released: US$2.07 loss per share (vs US$1.64 loss in 1Q 2021)

Sage Therapeutics and Biogen Initiate Rolling Submission of New Drug Application (NDA) to U.S. Food and Drug Administration for Zuranolone for the Potential Treatment of Major Depressive Disorder (MDD)

Sage Therapeutics, Inc. to Report Q1, 2022 Results on May 03, 2022

Sage Therapeutics Announces Presentation of Promising Results from the Phase 2 Luminary Study of Sage-718 in Patients with Mild Cognitive Impairment and Mild Dementia Due to Alzheimer’s Disease

Full year 2021 earnings: EPS in line with expectations, revenues disappoint

Sage Therapeutics, Inc. Provides Business Update

Investor sentiment deteriorated over the past week

Sage Therapeutics, Inc and Biogen Inc Announce Phase 3 CORAL Study Met its Primary and Key Secondary Endpoints

Sage Therapeutics and Biogen Announce New Analyses from the LANDSCAPE Clinical Development Program of Zuranolone in MDD Presented at the American College of Neuropsychopharmacology Congress

Sage Therapeutics and Biogen Announce Positive, One-Year Zuranolone 50 mg Data in the Ongoing Open-Label SHORELINE Study in Patients with MDD

Third quarter 2021 earnings released: US$2.21 loss per share (vs US$2.03 loss in 3Q 2020)

President recently bought €861k worth of stock

Second quarter 2021 earnings released: US$1.83 loss per share (vs US$2.63 loss in 2Q 2020)

Sage Therapeutics, Inc.(NasdaqGM:SAGE) dropped from Russell 3000E Growth Index

Independent Chairman recently bought €825k worth of stock

Sage Therapeutics, Inc. and Biogen Inc. Announce Positive Pivotal Phase 3 Results for Zuranolone, an Investigational Two-Week, Once-Daily Therapeutic Being Evaluated for Major Depressive Disorder

Investor sentiment improved over the past week

Sage Therapeutics, Inc. to Host Sage Science Spotlight: SAGE-718 In Depth

First quarter 2021 earnings released: US$1.64 loss per share (vs US$2.44 loss in 1Q 2020)

Chief Operating Officer has left the company

Sage Therapeutics, Inc. Announces Continued Positive Zuranolone Data for Both 30 Mg and 50 Mg Doses in Open-Label SHORELINE Study in Patients with MDD

Sage Therapeutics, Inc. Announces Departure of Mike Cloonan as Chief Operating Officer, Effective May 3, 2021

Investor sentiment deteriorated over the past week

Revenue beats expectations